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NO. 25 MAY 2019 Introduction 
The Hidden Dangers of Falsified and 
Substandard Medicines 
Developing Countries Are Most Affected by the Illegal Trade 
Judith Vorrath and Maike Voss 
When talking about health risks in developing countries, many people think of 
events such as the Ebola virus epidemic in 2014 and 2015 in West Africa. The effects 
of trade in falsified and substandard medicines are far less known. Developing 
countries are particularly affected since they are easy targets for the illegal trade 
due to insufficient regulations and controls as well as limited access to health care. 
The health and (socio-)economic consequences are severe. Moreover, criminal net-
works make large profits, usually without having to fear any significant punishment. 
The German government can push for a stronger focus on the issue at the World 
Health Assembly in May 2019. Germany’s bilateral engagement should, above all, 
support developing countries in making drug supply chains safer. 
 
According to World Health Organization 
(WHO) data from 2017, about one in ten 
medicines in middle- and low-income coun-
tries is substandard or falsified. Based on 
the WHO definition, this means that drugs 
are deliberately faked, are not approved 
for the destination market, or do not meet 
quality standards despite authorisation. 
Few cases have generated media responses 
like the one concerning the illegal produc-
tion in the Middle East of the amphetamine-
type stimulant Captagon, which was alleged-
ly distributed systematically to fighters of 
the “Islamic State”. In most cases, the illegal 
business in pharmaceutical products at-
tracts little attention. 
Between 2013 and 2017, 42 per cent of 
all reports sent to the WHO Global Surveil-
lance and Monitoring System on substand-
ard and falsified medicines worldwide came 
from Africa. Overall, flaws are most fre-
quently reported for antibiotics and drugs 
used to treat malaria. This also puts at risk 
the achievement of the Sustainable Devel-
opment Goal for good health and well-being 
(Goal 3), which concerns access to universal 
health care services and safe, effective, 
quality, and affordable essential medicines 
(Target 3.8). However, the damage caused 
by substandard and falsified medicines is 
much more multifaceted. 
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Risks and Implications of Falsified 
and Substandard Drugs 
Substandard and falsified antimalarials 
cause an estimated 116,000 deaths annually 
in sub-Saharan Africa, according to a WHO 
study. The underlying report’s focus is most-
ly on medicines that have been fraudulent-
ly manufactured. These medical products 
deliberately endanger the health of patients 
when containing no or false active ingredi-
ents. In particular, substandard pharmaceu-
ticals contribute to antimicrobial resistance. 
People with limited access to health care 
services or who are dependent on medical 
treatment for a longer period of time are 
most affected. 
In addition, there is financial damage 
for patients, but also for companies and 
the economy as a whole. In the case of anti-
malarials in sub-Saharan Africa, the esti-
mated annual cost to patients and health 
care is $38.5 million due to additional after-
care. In turn, substitute ingredients added 
to falsified medicines can pose additional 
health risks that require further and longer 
treatment. Scandals about fake drugs and 
ineffective and harmful therapies also 
undermine trust in the health care system. 
Those affected may use its services less 
often or only very late. 
Apart from the effects on public health, 
criminal networks generate high profits 
through the illicit trade in pharmaceuticals. 
However, this trade often has no visible con-
sequences on public safety. Thus, the dan-
gers associated with it tend to be hidden 
and are often underestimated. 
Illicit Trade and Pharmaceutical 
Crime 
Substandard medical products are often the 
result of a lack of care during their manu-
facture. Yet, they might enter legal supply 
chains – running across different countries 
or even continents – at various points. 
Sometimes such drugs are also traded il-
legally. In contrast, falsified medicines are 
produced deliberately – sometimes clan-
destinely, but also by officially registered 
pharmaceutical companies that basically 
serve as fronts. The most commonly named 
countries of origin for these fraudulent 
drugs are China and India, where active 
ingredients, but also components like the 
packaging or the labelling are faked to 
deceive consumers. To ensure that the 
products do not attract attention in simple 
laboratory tests, active ingredients are 
sometimes added, but rarely in adequate 
amounts. Ultimately, falsified medicines 
reach the end-user via illegal distribution 
channels or they find their way into legal 
supply chains. 
According to an Interpol report from 
2014, traditional organised crime is involved 
in this trade to a limited extent. As far as it 
is known, informal international networks 
with structures similar to those of genuine 
enterprises tend to dominate the illegal 
business. However, apart from a small steer-
ing group, their members usually do not 
know each other. The value of the trade in 
counterfeit medicines, which is increasingly 
taking place online, is estimated at $70 to 
$200 billion annually. 
Pharmaceutical crime varies greatly from 
region to region. Developing countries in 
Africa and South-East Asia are of particular 
interest as target markets for fraudulent 
medicines. Weak health systems, combined 
with miscalculations concerning demand of 
health services, offer favourable conditions 
there. Although the spending on pharma-
ceuticals is lower overall in developing coun-
tries, demand is rising while regulatory 
instruments are weak. Moreover, large sec-
tions of the population still have no access 
to adequate and high-quality health care. 
At the same time, illegal distribution via 
online pharmacies is less important than in 
Europe, for example. This is because market 
access for predominantly imported drugs is 
poorly regulated in many developing coun-
tries. Various medicines are also sold on the 
street and in barely controlled shops. In ad-
dition, drugs can easily be smuggled, espe-
cially in cargo containers. Such trafficked 
pharmaceutical products are also misused, 
like the painkiller Tramadol in West Africa. 
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In this case, illicitly traded medicine used 
as a substitute for heroin leads to further 
health problems. 
As part of the 10-day operation ACIM 
(Action against Counterfeit and Illicit Medi-
cines), which was carried out by 16 African 
customs administrations in 2016, pharma-
ceuticals worth around €52 million were 
confiscated. But such internationally sup-
ported operations remain selective. There is 
a fundamental lack of technologies to guar-
antee product safety and enable traceabil-
ity. In practice, countries are particularly 
short of laboratories for quality control, and 
effective prosecution is a major challenge. 
Moreover, the scope of international 
cooperation is limited. Among the members 
of the Permanent Forum on International 
Pharmaceutical Crime as an operational 
platform, for example, the only developing 
country is South Africa. As the risk of being 
exposed and punished is rather low, the 
profits of criminal networks remain high. 
In addition to prosecuting criminal net-
works, there is a need for approaches fo-
cussing on markets and supply chains that 
offer developing countries appropriate 
solutions. 
Making Supply Chains Safer 
So far, there is no global regulatory frame-
work addressing the illicit trade in medical 
products. The Council of Europe’s Medi-
crime Convention is a binding international 
instrument that can also be ratified by non-
member states. However, only three African 
countries have made use of this option so 
far. This makes it all the more important to 
support regional and national measures 
that enable developing countries to keep 
low-quality and harmful medicines out of 
their markets. In line with the WHO moni-
toring system (“prevent, detect, respond”), 
however, these measures should not only 
be reactive but focus on the whole supply 
chain, up to the end-consumer. 
Firstly, imports are of particular rele-
vance. Developing countries generally im-
port most medicines or receive them from 
aid organisations. However, in places where 
domestic production increases, measures 
need to be extended to ensure the quality of 
the medicines produced. If production is 
poorly controlled – while at the same time 
there is better monitoring in countries such 
as China – this can result in increased 
fraudulent activities. 
Secondly, regulation has to be more 
targeted. The number of officially approved 
entry points for pharmaceutical products 
can be reduced, all while ensuring that prod-
ucts are distributed nation-wide to the end-
consumer. Together with stronger network-
ing between health actors, pharmaceutical 
regulatory authorities, customs, and law 
enforcement, this can help to significantly 
improve surveillance, as has been the case 
in Nigeria since 2003. Moreover, in many 
countries, there are no specific laws for 
pharmaceutical crimes; rather, they treat 
the relevant cases as simple fraud or the 
infringement of intellectual property rights. 
Legislative proposals should distinguish 
between deliberate fakes and infringements 
of intellectual property rights in cases where 
the composition and effects of the drugs are 
not objectionable. Otherwise, the author-
ities will be overloaded with prosecuting 
less serious offences. 
Thirdly, when controlling the access, the 
main difficulties lie in the quick identifica-
tion of low-quality and falsified medicines 
and appropriate follow-up processes, such 
as their complete removal from distribution 
channels. Warnings on potentially affected 
drugs have to be circulated among the 
authorities and, if necessary, they have to 
be recalled. Ideally, after medicines have 
been seized, there should be investigations 
to identify those responsible for the illegal 
trade. 
Fourthly, effective approaches are need-
ed to control the quality of medicines when 
distributed and sold to consumers or pa-
tients. In European Union countries, manu-
facturers, distributors, and pharmacies 
check the authenticity of prescription medi-
cines by means of security features on the 
packaging and consolidate data on distribu-
tion channels in a European drug verifica-
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tion system. In the medium term, there 
should be procedures without gaps along 
the supply chain in developing countries, 
and these should be coordinated regionally, 
as far as possible. However, as long as there 
are no comprehensive “track and trace” 
systems, local organisations can also moni-
tor medicines with inexpensive rapid tests 
– a practice that can be accompanied by 
research projects. Countries such as Ghana 
are working with apps that can be used to 
check and report the codes on packaging. 
Here, however, the burden of monitoring 
basically lies with the consumer. Raising 
the awareness of the population is, there-
fore, essential in this context. 
Starting Points for Multilateral 
and Bilateral Engagement 
At the World Health Assembly in May, 
there are several starting points for Germa-
ny to address the issue at the interface of 
health and security. The international 
pharmaceutical industry could be obliged 
to develop a common monitoring system 
for falsified and substandard medicines 
based on the European model. This would 
allow for detecting anomalies at an early 
stage – both inside and outside companies 
– especially if these reports were also sent 
to the WHO Global Surveillance and Moni-
toring System. This way, the information 
would not harm an individual company, 
but rather increase the security level of the 
whole supply chain. The activities of the 
working groups under the WHO mecha-
nism on substandard and falsified medical 
products are also important. Germany 
could step up its commitment in this field. 
However, representatives from only 53 of 
the 194 WHO member states took part in 
the last meeting of the mechanism, in 
November 2018, which shows that many 
countries are not actively involved. Thus, 
it would be important to promote ex-
changes among developing countries beyond 
individual regional conferences. Last but 
not least, bilateral support remains essen-
tial. Two fundamental aspects need to be 
taken into account here. 
First, technical assistance in the health 
and security sectors must systematically 
address the integrity of the actors involved. 
From the procurement of drugs to the pros-
ecution of serious forms of pharmaceutical 
crime, susceptibility to corruption must 
be reduced. It is not all about know-how, 
skills, and equipment; control mechanisms 
and checks and balances within and be-
tween authorities are also important. The 
procurement of safe medicines, especially 
within the framework of development co-
operation, is also supported through certi-
fications and training courses offered by 
the WHO, among others. 
Second, access to safe, effective, and af-
fordable medicines must be improved over-
all. Otherwise, there will continue to be a 
high demand for cheap – but often unreli-
able – pharmaceuticals that are sold infor-
mally. Programmes financed by Germany to 
strengthen health systems should include 
the monitoring and control of supply chains 
as part of universal health coverage. 
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